Misoprostol+Oxytocin vs. Carbetocin in CS

• Status: Completed
• Trial end date: 2020-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

This prospective randomized double-blind clinical trial will be conducted at Ain-Shams University Maternity Hospital, Cairo, Egypt. Patients eligible for elective lower segment cesarean section will be randomized to 2 groups. Group 1: will receive 400 ug misoprostol following + 10 IU oxytocin intravenous slowly after cord clamping. Group 2: will receive 100 ug carbetocin intravenous after cord clamping.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Carbetocin; Misoprostol; Oxytocin

Criteria

Inclusion Criteria:

• Women with singleton pregnancy Women scheduled for elective CS full term (gestational age ≥37 weeks).

Exclusion Criteria:

• hypersensitivity to oxytocin, carbetocin or prostaglandins

• contraindication to prostaglandins (e.g. glaucoma)

• history of significant heart disease

• severe asthma

• epilepsy

• history or evidence of liver

• renal or vascular disease

• history of coagulopathy

• thrombocytopenia or anticoagulant therapy

• women with HELLP syndrome

• eclampsia

• women presenting by placental abruption

• contraindication to spinal anesthesia as carbetocin is licensed for use with regional anesthesia only.